SAB Biotherapeutics (SABS) is a pre-revenue clinical-stage biopharmaceutical company. Under a liquidation lens as of March 31, 2026, recovery to equity is driven almost entirely by liquid financial assets following the March 2026 public offering which generated approximately $93.6 million in aggregate net proceeds. Total assets reported at $248.5 million against total liabilities of $21.2 million yield GAAP book equity of $227.2 million. However, applying liquidation haircuts materially compresses this figure. Cash and cash equivalents of $20.5 million recover at 100%. Short-term investments of $86.9 million and long-term investments of $110.2 million (predominantly U.S. treasury securities, corporate bonds, and money market funds per MD&A) are marked at fair value and recover near 100%; unrealized losses of $0.41 million are immaterial against the $185.7 million AFS debt securities portfolio. Equity securities (ETF/mutual fund positions) of $11.4 million recover at fair value. Prepaid expenses of $3.8 million recover at modest discount; accrued investment income of $1.6 million recovers near par. PP&E gross of $31.9 million less accumulated depreciation of $18.1 million yields net book value of $13.8 million; applying a 50-60% liquidation haircut reduces recoverable value to approximately $6.9-8.3 million. Finance lease ROU asset of $3.5 million and operating lease ROU asset of $2.9 million recover at zero under liquidation (lease obligations survive). Intangibles: none separately tagged; intellectual property associated with the transchromosomic cattle platform and SAB-142 IND carries zero liquidation value. On the liability side: current liabilities of $9.9 million and non-current liabilities of $11.4 million (including warrant liability of $6.1 million at fair value, finance lease $3.1 million non-current, operating lease $2.2 million non-current) are taken at face value. The Emergent BioSolutions MSA executed April 28, 2026 (subsequent event) imposes a $36 million minimum aggregate spend obligation post-FDA approval over five years, with termination-for-cause provisions requiring payment of remaining minimum annual spend less saved costs. This contingent obligation is not on-balance-sheet as of March 31, 2026 and is not separately XBRL-tagged; it is disclosed only in the subsequent events footnote. The Sanford lease amendment (April 1, 2026) reduces monthly payments to ~$33 thousand, modestly decreasing the operating lease liability stack going forward. Accumulated deficit stands at $129.8 million. Net loss for Q1 2026 was $18.9 million versus $5.2 million in Q1 2025, reflecting Phase 2b SAFEGUARD trial ramp. Operating cash burn was $14.3 million in Q1 2026 versus $7.8 million in Q1 2025. The company discloses going concern runway through twelve months from filing date based on existing resources. The MFFAIS liquidation value of $5.4 million reflects a highly compressed estimate relative to the filing's liquid asset base, likely reflecting the warrant liability, lease obligations, and operating burn rate assumptions. The primary recovery driver is the $216+ million liquid investment and cash portfolio; recovery to equity under liquidation is positive but subject to realization of the investment portfolio at or near fair value and full settlement of all liabilities at face.
▼ Community Notes